ِDezAzma

Abstract Oxidative stress represents a fundamental pathological mechanism connecting metabolic dysfunction, chronic inflammation, and progressive cellular injury. Emerging evidence indicates that glucagon-like peptide-1 (GLP-1) receptor signaling extends beyond its classical incretin function in glucose regulation and acts as a critical molecular interface between metabolic control, redox homeostasis, and cellular protection [1–3]. Activation of GLP-1 pathways […]

Mechanisms, Clinical Benefits, Safety Monitoring, and Nursing Considerations Introduction Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a rapidly expanding class of incretin-based therapies originally developed for the management of type 2 diabetes mellitus (T2DM). Their clinical applications have expanded significantly due to their beneficial effects on weight management, cardiovascular risk reduction, and metabolic disease modification.¹ […]

GLP-1 receptor agonists are incretin-based therapies initially developed for type 2 diabetes mellitus and now widely used in obesity and cardiometabolic risk management. They mimic endogenous glucagon-like peptide-1 (GLP-1), a gut-derived hormone involved in glucose regulation and appetite control. 1. Mechanism of Action GLP-1 receptor agonists act through multiple physiological pathways: Enhance glucose-dependent insulin secretion […]